Catalent (NYSE:CTLT – Get Rating) had its price target cut by Barclays from $62.00 to $58.00 in a research note published on Tuesday, The Fly reports. They currently have an overweight rating on the stock.

A number of other equities analysts have also weighed in on CTLT. Argus lowered Catalent from a buy rating to a hold rating in a research note on Monday, November 7th. KeyCorp decreased their target price on Catalent from $125.00 to $85.00 and set an overweight rating on the stock in a research note on Wednesday, November 2nd. StockNews.com cut Catalent from a hold rating to a sell rating in a report on Saturday, November 5th. TheStreet cut Catalent from a b- rating to a c+ rating in a report on Friday, October 28th. Finally, Royal Bank of Canada cut their price objective on Catalent from $125.00 to $73.00 and set an outperform rating for the company in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus price target of $92.40.

Catalent Stock Performance

NYSE:CTLT opened at $53.65 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.08 and a current ratio of 2.86. Catalent has a 52-week low of $40.69 and a 52-week high of $115.33. The firm has a market cap of $9.66 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 3.45 and a beta of 1.24. The business's fifty day moving average is $46.75 and its 200 day moving average is $71.35.

Insider Activity at Catalent

In related news, SVP Michael J. Grippo sold 2,451 shares of the stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the completion of the sale, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Catalent news, SVP Michael J. Grippo sold 2,451 shares of the stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $65.83, for a total value of $161,349.33. Following the completion of the sale, the senior vice president now owns 17,792 shares in the company, valued at approximately $1,171,247.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ricky Hopson sold 643 shares of the stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $49.36, for a total value of $31,738.48. Following the completion of the sale, the insider now owns 16,452 shares of the company's stock, valued at approximately $812,070.72. The disclosure for this sale can be found here. Insiders sold 3,874 shares of company stock worth $233,414 in the last ninety days. 0.58% of the stock is owned by company insiders.

Institutional Investors Weigh In On Catalent

Several institutional investors and hedge funds have recently bought and sold shares of CTLT. Bellevue Group AG purchased a new stake in Catalent in the 3rd quarter worth approximately $34,000. CX Institutional bought a new position in shares of Catalent in the 2nd quarter worth approximately $37,000. Clear Street Markets LLC raised its position in shares of Catalent by 408.1% in the 2nd quarter. Clear Street Markets LLC now owns 376 shares of the company's stock worth $40,000 after acquiring an additional 302 shares in the last quarter. Motco bought a new position in shares of Catalent in the 3rd quarter worth approximately $41,000. Finally, Alta Advisers Ltd bought a new position in shares of Catalent in the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 99.38% of the company's stock.

Catalent Company Profile

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Recommended Stories

• Get a free copy of the StockNews.com research report on Catalent (CTLT)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.